Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
RedHill Biopharma Ltd.
About
  2. Companies
  3. RedHill Biopharma Ltd.
  4. Products
  5. RedHill - Model RHB-104 - ...

RedHill - Model RHB-104 -Groundbreaking Proprietary Investigational Drug

SHARE

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

Most popular related searches
multiple sclerosis
crohn’s disease
anti-inflammatory
gastrointestinal tract
gastrointestinal disease
disease development
inflammatory anti
gastrointestinal
drug formulation

RHB-104`s development is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori.

RHB-104 is being developed for multiple indications, including:

  • Crohn`s disease - positive top-line results from a first Phase 3 study for Crohn`s disease (MAP U.S. study) were announced in July 2018
  • Multiple sclerosis - a Phase 2a proof of concept study for multiple sclerosis was completed in Israel with encouraging top-line final results announced December 2016